Text Size

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Department of Defense
Information provided by:
PTC Therapeutics
ClinicalTrials.gov Identifier:
NCT00508586
First received: July 26, 2007
Last updated: April 6, 2012
Last verified: April 2012
History of Changes
  Purpose

Formation of new blood vessels (angiogenesis) is important for tumor growth in metastatic breast cancer. It is known that tumors make a protein called vascular endothelial growth factor (VEGF) and there are higher levels of VEGF in the tumors and blood of many women with metastatic breast cancer. VEGF stimulates the formation of blood vessels that supply the tumor with nutrients and oxygen. PTC299 is an oral drug that has been shown to decrease production of VEGF in animal models of human cancer. In these animal models, oral PTC299 administration decreases VEGF levels in the tumor and in the bloodstream, decreases blood vessel numbers in the tumor, and significantly slows or halts tumor growth. Safety studies in research animals indicate good tolerability at doses and drug levels that are higher than those planned for the clinical studies. Results from Phase 1a studies in healthy volunteers indicate that PTC299 achieves levels of PTC299 in the bloodstream that are known to be active in animal models of human cancer. This Phase 1b study is designed to test the hypothesis that PTC299 will be tolerable and will show evidence of VEGF reduction and antitumor activity when administered orally in combination with anastrozole (Arimidex®), letrozole (Femara®), or exemestane (Aromasin®) to women with metastatic breast cancer.


Condition Intervention Phase
Metastatic Breast Cancer
 Drug: PTC299
 Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1b Study to Assess the Safety, Feasibility, Pharmacokinetics, and Activity of PTC299 Monotherapy or Combination Therapy With Hormonal Agents in Patients With Metastatic Breast Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by PTC Therapeutics:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) within the tested dose range. [ Time Frame: 6 Weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Overall safety profile [ Time Frame: 6 Weeks ] [ Designated as safety issue: Yes ]
  • Study drug compliance [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetics [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • Circulating angiogenic markers [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • Tumor perfusion as assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • Tumor metabolism as assessed by fluorodeoxyglucose positron emission tomography (FDG-PET) [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
  • Antitumor activity as assessed by computed tomography (CT) scans and tumor markers [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 36
Study Start Date: November 2007
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
PTC299 with an aromatase inhibitor
 Drug: PTC299
PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)

Detailed Description:

The study will be conducted in 2 stages. In Stage 1 of the study, successive groups of 3 to 6 patients will receive progressively higher PTC299 dose levels; in this stage, treatment will be given in repeated 6-week cycles consisting of 4 weeks of oral PTC299 twice per day followed by a 2-week, no-drug period. During Stage 2, study candidates must be women with natural or induced suppression of ovarian function to post-menopausal levels who are receiving or are candidates for hormonal therapy. These subjects will receive continuous administration of PTC299, 100 mg/dose BID, in repeated 6-week cycles in combination with continuous administration of one of 3 hormonal agents. All planned PTC299 dose levels in all stages are expected to achieve circulating blood levels of PTC299 known to be active in animal models of human cancer. Treatment for each patient can continue as long as the therapy appears to be safely offering tumor control to that patient. Up to 36 evaluable patients will be accrued across both stages.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Major Eligibility Criteria:

  1. Female sex.
  2. Age ≥18 years.
  3. Body weight 40-100 kg.
  4. ECOG performance status of 0 or 1.
  5. Histologically or cytologically confirmed adenocarcinoma of the breast.
  6. Presence of metastatic disease not amenable to surgery, radiation therapy, or chemoradiotherapy with curative intent.
  7. No active second metastatic malignancy other than breast cancer.
  8. No unstable brain or leptomeningeal disease.
  9. Discontinuation of other therapies (except for anastrozole, letrozole, or exemestane) for the treatment of breast cancer and resolution of any acute toxic effects of prior therapies.
  10. Adequate bone marrow, liver, and kidney function.
  11. No uncontrolled hypertension, major bleeding, HIV infection or recent acute cardiovascular event.
  12. If sexually active and not postmenopausal or surgically sterile, willingness to abstain from sexual intercourse or employ an effective barrier method of contraception during the study drug administration and follow-up periods.
  13. No pregnancy or breast-feeding.
  14. Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
  15. Willingness to provide informed consent. In addition to the criteria noted above, Stage 2 subjects must also have natural or induced suppression of ovarian function to post-menopausal levels and be receiving or be a candidate for hormonal therapy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00508586

Locations
United States, Indiana
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States, 46202
United States, New York
New York University Clinical Cancer Center
New York, New York, United States, 10016
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
PTC Therapeutics
Department of Defense
Investigators
Study Director: Jay Barth, MD PTC Therapeutics, Inc.
  More Information

Additional Information:
PTC Therapeutics, Inc. web site  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Leslie Callahan, RN, MS, PTC Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT00508586     History of Changes
Other Study ID Numbers: PTC299-ONC-003-BRC, BC050203
Study First Received: July 26, 2007
Last Updated: April 6, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by PTC Therapeutics:
Breast cancer
PTC299
VEGF
 Angiogenesis
Post-transcriptional control
Aromatase inhibitors

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
 Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013